Latest stories

  • in

    USFDA nod to Zydus Lifesciences Estradiol Transdermal System for postmenopausal osteoporosis prevention

    USFDA approves Zydus Lifesciences Tavaborole Topical Solution to treat fungal toenail infections

    Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day (weekly) (USRLD: Menostar Transdermal System). Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, […] More

  • in

    Lower-Dose Regimens of Exemestane Effective in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer

    Lower-Dose Regimens of Exemestane Effective in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer

    According to research reported in JAMA Oncology, based on findings from a phase IIb trial, 25 mg exemestane thrice weekly is noninferior to the standard dosing of 25 mg once daily pertaining to reduction of serum estradiol among postmenopausal patients with stage 0 to II estrogen receptor (ER)-positive breast cancer. Minimal effective dose is an […] More